ultragenyx.com - RARE Total Stockholders' Equity

The Ultragenyx Pharmaceutical (RARE) price chart reflects the dynamics of a business anchored in the high-margin rare disease therapy sector where no alternatives exist. The current metric stands at -0.29. The firm maintains an impeccable reputation for developing treatments for previously hopeless conditions. Leading geneticists drive this success, with their research supported by substantial investments and a commitment to saving patients with critical diagnoses.

RARE: ultragenyx.com Company Book Value 07/04/2022 - 10/31/2026

Financial and market metric breakdowns for Ultragenyx (RARE)

- current price and projected stock value:

Price Performance Chart Ultragenyx Corp|RARE - Analyst Consensus Forecast

- issuer market value details:

Market Value Ultragenyx Pharmaceutical Inc.|RARE - Enterprise Value

- company book value details:

Equity per Share Ultragenyx|RARE - Company Book Value|Capitalization to Book Value Ratio ultragenyx.com|RARE - Company Total Assets

- company total debt and liquidity indicators:

Total Debt to Capital Ultragenyx Pharmaceutical|RARE - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Ultragenyx Pharmaceutical Inc.|RARE - Company Debts|Debt to Book Capitalization Ratio Ultragenyx Pharmaceutical Inc.|RARE - Company Long-Term Liabilities|Amount of Current Liabilities Ultragenyx|Intermediate Coverage Ratio ultragenyx.com

- earnings and valuation multiples information:

RARE - Net Profit

Initial company analysis:Ultragenyx Corp - RARE

Book value capitalization represents a daily calculation of net assets minus all debt obligations, reflecting the real value of the business regardless of market volatility. For Ultragenyx Pharmaceutical (RARE), which is protected by exclusive gene therapy patents, analyzing the firm's book value of equity allows for an assessment of the company's fundamental stability in the absence of price competition and helps determine a fair entry threshold.

Direct competitors